Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Ascletis eyes quarterly GLP-1 dosing following phase 2 readout
Ascletis posted phase 2 data on its ultra-long-acting GLP-1, generating early evidence that the formulation may support quarterly maintenance dosing.
Nick Paul Taylor
Mar 10, 2026 8:20am
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
Mar 9, 2026 8:25am
Zealand's Zupreme serves up to 10.7% mean weight loss
Mar 5, 2026 4:44pm
How GLP-1s help the heart relax: study
Mar 2, 2026 7:01pm
Novo's triple G candidate drives 20% weight loss in phase 2
Feb 24, 2026 7:42am
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Feb 10, 2026 9:25am